Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Sintomi gastrointestinali e tolleranza nei lattanti alimentati con formula infantile a base di latte di capra o di mucca (MESK-2)

13 novembre 2026 aggiornato da: Ausnutria Hyproca B.V.

Effetto di una Formula per Lattanti a Base di Latte di Capra sui Sintomi Gastrointestinali e sulla Tollerabilità nei Lattanti Sani a Termine: uno Studio Controllato Randomizzato in Doppio Cieco

This randomized controlled double-blind study will compare the effect of a commercially available goat milk formula to a cow's milk formula on gastrointestinal symptoms and tolerance, and infections in infants.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

144

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Riyadh, Arabia Saudita
        • Reclutamento
        • King Faissal Specialist Hospital & Research Centre
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 2 settimane a 2 mesi (Bambino)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age between 14 days and 90 days.
  • Healthy singleton term infants born between 37 weeks and 42 weeks of gestation.
  • Infants who have received CMF for at least 7 consecutive days.
  • Exclusive formula feeding.
  • Cow's Milk-related Symptoms Score (CoMiSS®) value at baseline of ≥6 and <10.
  • Parents' or caregivers, aged ≥18 years, willing to give informed consent and adhere to study protocol

Exclusion Criteria:

  • Exclusively or partially feeding with human milk
  • Introduced to solid food, supplementary feeding, use of pre- and/or probiotics as a supplement
  • Congenital or recurrent chronic conditions and/or malabsorption that could interfere with study parameters.
  • Diagnosed cow's milk allergy (CMA) or suspected to have CMA, soy allergy, fish allergy, egg allergy and/or lactose intolerance.
  • Receiving medication (on own initiative or prescription) with regard to FGID (i.e. reflux medication)
  • Sibling already participating in this study
  • Participation in another clinical trial

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Intervention group

Goat milk-based infant formula

Study product is administered on demand until the age of 6 months.

Comparatore attivo: Control group

Cow's milk-based infant formula

Study product is administered on demand until the age of 6 months.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Gastrointestinal symptoms as determined by CoMiSS
Lasso di tempo: Difference between groups at Day 14 of the intervention

The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms).

Difference between groups at Day 14 of the intervention
Gastrointestinal tolerance as determined by IGSQ
Lasso di tempo: Difference between groups at the end of the intervention at 24 weeks

The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress.

Difference between groups at the end of the intervention at 24 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Gastrointestinal symptoms throughout the study as determined by CoMiSS
Lasso di tempo: From enrollment to the end of the intervention at 24 weeks

The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms).

From enrollment to the end of the intervention at 24 weeks
Gastrointestinal tolerance throughout the study as determined by IGSQ
Lasso di tempo: From enrollment to the end of the intervention at 24 weeks

The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress.

From enrollment to the end of the intervention at 24 weeks
Occurrence, duration and severity of gastrointestinal infections as determined by Vesikari
Lasso di tempo: From enrollment to the end of the intervention at 24 weeks

The Vesikari Clinical Severity Scoring System includes a e-diary card completed by parents, to identify rotavirus gastroenteritis episodes. The Vesikari Clinical Severity Scoring System Parameters score ranges from 0 to 20 with score <7 as mild symptoms and score 10 to 20 as severe symptoms.

From enrollment to the end of the intervention at 24 weeks
Occurrence, duration and severity of respiratory infections as determined by CARIFS
Lasso di tempo: From enrollment to the end of the intervention at 24 weeks

Canadian Acute Respiratory Illness and Flu Scale is a validated parental questionnaire, to measure the disease severity of children with acute respiratory illness (ARI) including influenza. CARIFS consists of 18 items covering three domains; symptoms (e.g., cough); function (e.g., play), and parental impact (e.g., clinginess). Each item is scored 0 to 3, with higher scores indicating greater severity of illness. The full scale ranges from 0 to 58. For children older than 5 years the full scale is used; for children younger than 5 years, 3 items (headache, sore throat, and muscle aches) are not used for assessment.

From enrollment to the end of the intervention at 24 weeks
Occurrence, duration and severity of ear infections as determined by AOM-SOS V5
Lasso di tempo: From enrollment to the end of the intervention at 24 weeks

The Acute Otitis Media Symptom Severity scale (AOM-SOS) Version 5.0 is psychometric scale used to measure the severity of symptoms in children with acute otitis media and has been validated for parent-reported use. A 6-point Likert scale ranging from 'No' to 'An extreme amount' is used to rate the presence of 5 symptoms related to acute otitis media over the preceding 24 hours. The AOM-SOS Version 5.0 total score is obtained by summing the scores on these 5 equally-weighted questions.

From enrollment to the end of the intervention at 24 weeks
Quality of life as determined by PedsQL
Lasso di tempo: From enrollment to the end of the intervention at 24 weeks

The Pediatric Quality of Life Inventory (PedsQL™) Infant Scales™ is a specific module of the PedsQL™. The objective of this validated questionnaire is to measure generic health-related quality of life in infants. Applicable for infants with acute and chronic health conditions and healthy infants. The questionnaire is composed of 36 items comprising 5 dimensions: physical functioning, physical symptoms, emotional functioning, social functioning and cognitive functioning. Higher scores means better HRQOL and fewer problems or symptoms. A 5-point Likert scale from is applied: 0 (Never) to 4 (Almost always). Scores are transformed on a scale from 0 to 100.

From enrollment to the end of the intervention at 24 weeks
Quality of life as determined by WHOQoL-BREF
Lasso di tempo: From enrollment to the end of the intervention at 24 weeks

The World Health Organization Quality of Life Questionnaire BREF (WHOQoL-BREF) is the shortened version of the WHOQoL-100. The WHOQoL-BREF measures quality of life within the context of an individual's culture, value systems, personal goals, standards of concerns. The measuring instrument consists of 26 items. The raw scoreis transformed to a 0-100 scale, where higher scores indicate higher perceived quality of life.

From enrollment to the end of the intervention at 24 weeks
Weight
Lasso di tempo: From enrollment to the end of the intervention at 24 weeks

Weight will be measured in kilograms.

From enrollment to the end of the intervention at 24 weeks
Height
Lasso di tempo: From enrollment to the end of the intervention at 24 weeks

Height will be measured in centimeters.

From enrollment to the end of the intervention at 24 weeks
Head circumference
Lasso di tempo: From enrollment to the end of the intervention at 24 weeks

Head circumference will be measured in centimeters.

From enrollment to the end of the intervention at 24 weeks
WHO z-scores
Lasso di tempo: From enrollment to the end of the intervention at 24 weeks

Subject's weight, length and head circumference will be used to calculate the WHO z-scores for weight-for-age, length-for-age, head circumference-for-age, weight-for-length.

From enrollment to the end of the intervention at 24 weeks
Fecal parameters
Lasso di tempo: Baseline, Day 14, Day 28, Week 12 and Week 24

The major fecal bacterial groups are defined using 16S RNA sequencing. Further fecal parameters (e.g. pH, SCFA, sIgA, A1AT) are determined with standard laboratory techniques.

Baseline, Day 14, Day 28, Week 12 and Week 24
Sleep and Crying episodes
Lasso di tempo: Baseline, Day 14, Day 28, Week 12 and Week 24

Sleep and crying episodes and duration are recorded for 24 hours prior to the visits in diaries.

Baseline, Day 14, Day 28, Week 12 and Week 24
Stool frequency & consistenty
Lasso di tempo: Baseline, Day 14, Day 28, Week 12 and Week 24

Stool frequency and consistency are recorded for 24 hours prior to visits in diaries.

Baseline, Day 14, Day 28, Week 12 and Week 24

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

26 agosto 2026

Completamento primario (Stimato)

1 settembre 2027

Completamento dello studio (Stimato)

1 settembre 2027

Date di iscrizione allo studio

Primo inviato

23 dicembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

6 gennaio 2026

Primo Inserito (Effettivo)

15 gennaio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • P24-150

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .